Eun Jung Park

Eun Jung Park

Auto-generated profile, based on publicly available information

Eun Jung Park

Department of Cancer Biomedical Science

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
HKHan Seok Koh
Han Seok Koh
CCChi Young Chang
Chi Young Chang
SJSae-Bom Jeon
Sae-Bom Jeon
HYHee Jung Yoon
Hee Jung Yoon
YAYe-Hyeon Ahn
Ye-Hyeon Ahn
EPEun Jung Park
Eun Jung Park
Inflammation is closely related to the extent of damage following cerebral ischaemia, and the targeting of this inflammation has emerged as a promising therapeutic strategy. Here, we present that hypoxia-induced glial T-cell immunoglobulin and mucin domain protein (TIM)-3 can function as a modulator that links inflammation and subsequent brain damage after ischaemia. We find that TIM-3 is highly expressed in hypoxic brain regions of a mouse cerebral hypoxia-ischaemia (H/I) model. TIM-3 is distinctively upregulated in activated microglia and astrocytes, brain resident immune cells, in a hypoxia-inducible factor (HIF)-1-dependent manner. Notably, blockade of TIM-3 markedly reduces infarct size, neuronal cell death, oedema formation and neutrophil infiltration in H/I mice. Hypoxia-triggered neutrophil migration and infarction are also decreased in HIF-1α-deficient mice. Moreover, functional neurological deficits after H/I are significantly improved in both anti-TIM-3-treated mice and myeloid-specific HIF-1α-deficient mice. Further understanding of these insights could serve as the basis for broadening the therapeutic scope against hypoxia-associated brain diseases.

1 May 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HKHyung-Seok Kim
Hyung-Seok Kim
CCChi Young Chang
Chi Young Chang
HYHee Jung Yoon
Hee Jung Yoon
KKKi Sun Kim
Ki Sun Kim
HKHan Seok Koh
Han Seok Koh
EPEun Jung Park
Eun Jung Park
T-cell immunoglobulin and mucin domain–containing molecule 3 (TIM-3), a potential immunotherapeutic target for cancer, has been shown to display diverse characteristics in a context-dependent manner. Thus, it would be useful to delineate the precise functional features of TIM-3 in a given situation. Here, we report that glial TIM-3 shows distinctive properties in the brain tumor microenvironment. TIM-3 was expressed on both growing tumor cells and their surrounding cells including glia and T cells in an orthotopic mouse glioma model. The expression pattern of TIM-3 was distinct from those of other immune checkpoint molecules in tumor-exposed and tumor-infiltrating glia. Comparison of cells from tumor-bearing and contralateral hemispheres of a glioma model showed that TIM-3 expression was lower in tumor-infiltrating CD11b+CD45mid glial cells but higher in tumor-infiltrating CD8+ T cells. In TIM-3 mutant mice with intracellular signaling defects and Cre-inducible TIM-3 mice, TIM-3 affected the expression of several immune-associated molecules including iNOS and PD-L1 in primary glia-exposed conditioned media (CM) from brain tumors. Further, TIM-3 was cross-regulated by TLR2, but not by TLR4, in brain tumor CM- or Pam3CSK4-exposed glia. In addition, following exposure to tumor CM, IFNγ production was lower in T cells cocultured with TIM-3–defective glia than with normal glia. Collectively, these findings suggest that glial TIM-3 actively and distinctively responds to brain tumor, and plays specific intracellular and intercellular immunoregulatory roles that might be different from TIM-3 on T cells in the brain tumor microenvironment. Significance: TIM-3 is typically thought of as a T-cell checkpoint receptor. This study demonstrates a role for TIM-3 in mediating myeloid cell responses in glioblastoma.

8 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCChi Young Chang
Chi Young Chang
Dong-Kug ChoiDong-Kug Choi
Dong-Kug Choi
DLDae Kee Lee
Dae Kee Lee
YHYoung Jun Hong
Young Jun Hong
EPEun Jung Park
Eun Jung Park
Myeloperoxidase (MPO) functions as a key molecular component of the host defense system against diverse pathogens. We have previously reported that increased MPO levels and activity is a distinguishing feature of rotenone-exposed glial cells, and that either overactivation or deficiency of MPO leads to pathological conditions in the brain. Here, we provide that modulation of MPO levels in glia by resveratrol confers protective effects on rotenone-induced neurotoxicity. We show that resveratrol significantly reduced MPO levels but did not trigger abnormal nitric oxide (NO) production in microglia and astrocytes. Resveratrol-induced down-regulation of MPO, in the absence of an associated overproduction of NO, markedly attenuated rotenone-triggered inflammatory responses including phagocytic activity and reactive oxygen species production in primary microglia and astrocytes. In addition, impaired responses of primary mixed glia from Mpo−/− mice to rotenone were relieved by treatment with resveratrol. We further show that rotenone-induced neuronal injury, particularly dopaminergic cell death, was attenuated by resveratrol in neuron-glia co-cultures, but not in neurons cultured alone. Similar regulatory effects of resveratrol on MPO levels were observed in microglia treated with MPP+, another Parkinson’s disease-linked neurotoxin, supporting the beneficial effects of resveratrol on the brain. Collectively, our findings provide that resveratrol influences glial responses to rotenone by regulating both MPO and NO, and thus protects against rotenone-induced neuronal injury.

1 August 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
CCChi Young Chang
Chi Young Chang
MSMi Jeon Song
Mi Jeon Song
SJSae-Bom Jeon
Sae-Bom Jeon
HYHee Jung Yoon
Hee Jung Yoon
DLDae Kee Lee
Dae Kee Lee
EPEun Jung Park
Eun Jung Park

5 February 2019 in Glia
Verified
Journal Article
Closed access
PDF file
CCChi Young Chang
Chi Young Chang
SJSae‐Bom Jeon
Sae‐Bom Jeon
HYHee Jung Yoon
Hee Jung Yoon
BCBum‐Kyu Choi
Bum‐Kyu Choi
SKSang Soo Kim
Sang Soo Kim
EPEun Jung Park
Eun Jung Park

1 December 2009 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
HKHan Seok Koh
Han Seok Koh
CLChangjin Lee
Changjin Lee
Kwangsoo LeeKwangsoo Lee
Kwangsoo Lee
EPEun Jung Park
Eun Jung Park
RSRho H. Seong
Rho H. Seong
SJSung Ho Jeon
Sung Ho Jeon
In the periphery, a galectin-1 receptor, CD7, plays crucial roles in galectin-1-mediated apoptosis of activated T-cells as well as progression of T-lymphoma. Previously, we demonstrated that NF-κB downregulated CD7 gene expression through the p38 MAPK pathway in developing immature thymocytes. However, its regulatory pathway is not well understood in functional mature T-cells. Here, we show that CD7 expression was downregulated by Twist2 in Jurkat cells, a human acute T-cell lymphoma cell line, and in EL4 cells, a mature murine T-cell lymphoma cell line. Furthermore, ectopic expression of Twist2 in Jurkat cells reduced galectin-1-induced apoptosis. While full-length Twist2 decreased CD7 promoter activity, a C-terminal deletion form of Twist2 reversed its inhibition, suggesting an important role of the C-terminus in CD7 regulation. In addition, CD7 expression was enhanced by histone deacetylase inhibitors such as trichostatin A and sodium butyrate, which indicates that Twist2 might be one of candidate factors involved in histone deacetylation. Based on these results, we conclude that upregulation of Twist2 increases the resistance to galectin-1-mediated-apoptosis, which may have significant implications for the progression of some T-cells into tumors such as Sezary cells.